This Article Full Text Full Text (PDF) All Versions of this Article: 44/4/471    most recent 01.HYP.0000142772.71367.65v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meiners, S. Articles by Stangl, K. Search for Related Content PubMed PubMed Citation Articles by Meiners, S. Articles by Stangl, K. Related Collections Other myocardial biology Remodeling Animal models of human disease Other Treatment

(Hypertension. 2004;44:471.)
© 2004 American Heart Association, Inc.

Scientific Contributions

Downregulation of Matrix Metalloproteinases and Collagens and Suppression of Cardiac Fibrosis by Inhibition of the Proteasome

Silke Meiners; Berthold Hocher; Andrea Weller; Michael Laule; Verena Stangl; Christoph Guenther; Michael Godes; Alexander Mrozikiewicz; Gert Baumann; Karl Stangl

From Medizinische Klinik (S.M., A.W., M.L., V.S., C.G., G.B., K.S.), Kardiologie and Center for Cardiovascular Research and Medizinische Klinik (B.H., M.G.), Nephrologie, Berlin, Germany; Institute of Clinical Pharmacology (A.M.), University Poznan, Poland.

Correspondence to Karl Stangl, MD, Medizinische Klinik, Charité, Schumannstrasse 20/21, D-10117 Berlin, Germany. E-mail karl.stangl{at}charite.de

Myocardial remodeling is an adaptive response of the myocardium to several forms of stress culminating in cardiac fibrosis, left ventricular dilation, and loss of contractility. The remodeling processes of the extracellular matrix are controlled by matrix metalloproteinases, which are in turn regulated by growth factors and inflammatory cytokines. The inflammatory transcription factor nuclear factor B has been implicated in the transcriptional regulation of several matrix metalloproteinases. Because activation of nuclear factor B in turn is essentially controlled by the ubiquitin-proteasome system, we investigated the hypothesis that inhibition of the proteasome may prevent activation of matrix metalloproteinases. We demonstrate here that inhibition of the proteasome in rat cardiac fibroblasts suppressed not only expression of matrix metalloproteinases 2 and 9, but also expression of collagen I1, I2, and III1 as determined by in-gel zymography and real-time reverse transcription–polymerase chain reaction. Moreover, myocardial expression of matrix metalloproteinases and collagens was effectively suppressed by systemic treatment of spontaneously hypertensive rats over 12 weeks with the proteasome inhibitor MG132, which resulted in a marked reduction of cardiac fibrosis (–38%) compared with control animals. We conclude that inhibition of the ubiquitin-proteasome system may provide a new and attractive tool to interfere with collagen and matrix metalloproteinase expression, and therefore might be of possible use in the therapy of myocardial remodeling.

Key Words: myocardial remodeling • collagen • fibrosis

This article has been cited by other articles:

				J. Herrmann, L. O. Lerman, and A. Lerman On to the road to degradation: atherosclerosis and the proteasome Cardiovasc Res, November 14, 2009; (2009) cvp333v2. [Abstract] [Full Text] [PDF]

				O. Tsukamoto, T. Minamino, and M. Kitakaze Functional alterations of cardiac proteasomes under physiological and pathological conditions Cardiovasc Res, September 4, 2009; (2009) cvp282v2. [Abstract] [Full Text] [PDF]

				N. Hedhli and C. Depre Proteasome inhibitors and cardiac cell growth Cardiovasc Res, August 7, 2009; (2009) cvp226v2. [Abstract] [Full Text] [PDF]

				S. Fineschi, M. Bongiovanni, Y. Donati, S. Djaafar, F. Naso, L. Goffin, C. Barazzone Argiroffo, J.-C. Pache, J.-M. Dayer, S. Ferrari-Lacraz, et al. In Vivo Investigations on Anti-Fibrotic Potential of Proteasome Inhibition in Lung and Skin Fibrosis Am. J. Respir. Cell Mol. Biol., October 1, 2008; 39(4): 458 - 465. [Abstract] [Full Text] [PDF]

				N. Hedhli, P. Lizano, C. Hong, L. F. Fritzky, S. K. Dhar, H. Liu, Y. Tian, S. Gao, K. Madura, S. F. Vatner, et al. Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1385 - H1393. [Abstract] [Full Text] [PDF]

				N. Awasthi, S. T. Wang-Su, and B. J. Wagner Downregulation of MMP-2 and -9 by Proteasome Inhibition: A Possible Mechanism to Decrease LEC Migration and Prevent Posterior Capsular Opacification Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 1998 - 2003. [Abstract] [Full Text] [PDF]

				H. Dreger, M. Lorenz, A. Kehrer, G. Baumann, K. Stangl, and V. Stangl Characteristics of Catechin- and Theaflavin-Mediated Cardioprotection Experimental Biology and Medicine, April 1, 2008; 233(4): 427 - 433. [Abstract] [Full Text] [PDF]

				Y. Takami, H. Nakagami, R. Morishita, T. Katsuya, T.-X. Cui, T. Ichikawa, Y. Saito, H. Hayashi, Y. Kikuchi, T. Nishikawa, et al. Ubiquitin Carboxyl-Terminal Hydrolase L1, a Novel Deubiquitinating Enzyme in the Vasculature, Attenuates NF-{kappa}B Activation Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2184 - 2190. [Abstract] [Full Text] [PDF]

				R. S.-Y. Foo, L. K. W. Chan, R. N. Kitsis, and M. R. Bennett Ubiquitination and Degradation of the Anti-apoptotic Protein ARC by MDM2 J. Biol. Chem., February 23, 2007; 282(8): 5529 - 5535. [Abstract] [Full Text] [PDF]

				S. Johar, A. C. Cave, A. Narayanapanicker, D. J. Grieve, and A. M. Shah Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase FASEB J, July 1, 2006; 20(9): 1546 - 1548. [Abstract] [Full Text] [PDF]